Abstract: Vasoplegia syndrome is a well known complication after cardiac surgery and has a significant morbidity and mortality. It is characterized by profound vasodilation and loss of systemic vascular resistance leading to hypotension. The pathogenesis of vasoplegia involves the activation of contact, coagulation and complement systems and the activation of leukocytes, platelets and endothelial cells resulting in an imbalance in the regulation of the vascular tone leading to postcardiac surgery vasoplegia. Multiple risk factors have been identified that help predict vasoplegia. Treatment requires mainly vasopressors, but hypotension can be refractory to vasopressors. Some studies suggest that methylene blue can reverse refractory hypotension in these patients and may prevent the development of the syndrome, but more studies are needed with this drug. In this review, we will discuss the pathophysiology of the vasoplegia syndrome and associated risk factors for this complication and briefly outline current therapeutic strategies.
C ardiac vasoplegia syndrome is a form of vasodilatory shock that occurs in 9% to 44% of patients after cardiopulmonary bypass (CPB) surgery. 1, 2 These patients have profound vasodilation and loss of systemic vascular resistance, resulting in severe hypotension despite high cardiac outputs and adequate fluid resuscitation. This leads to inadequate tissue perfusion and metabolic acidosis. Treatment often requires high doses of vasopressors to maintain adequate blood pressure postoperatively, and sometimes, this vasoplegia becomes refractory to vasopressors, resulting in high morbidity and mortality. 3 This complication is largely managed by cardiac anesthesiologists and cardiac surgeons. We provide a brief review for primary care physicians and intensivists who may participate in the care of these patients.
DISCUSSION Pathophysiology
Cardiac vasoplegia syndrome has become a wellrecognized complication of cardiac surgery requiring CPB and is characterized by significant hypotension, high or normal cardiac outputs, low systemic vascular resistance and an increased requirement for vasopressors. 4 This syndrome reflects the complex interactions among plasma proteins, leukocytes, platelets and endothelial cells. Surgical trauma and the use of CPB with exposure of blood to foreign surfaces in the pump and tubing activate multiple enzyme pathways and stimulate production of systemic inflammatory mediators and neurohumoral factors. 1 The pathophysiologic basis for this syndrome also depends on patient characteristics and the surgical procedure. The net result is a systemic inflammatory response syndrome (SIRS) and transient vascular dysfunction resulting in vasodilation and resistance to vasopressors. 5 Plasma proteins are immediately absorbed to biomembranes when blood passes through the CPB equipment. This protein layer is densely packed and immobile, and some proteins undergo confirmation changes and express "receptors" for cells and other proteins. 6, 7 This results in the activation of the contact system, the extrinsic coagulation pathway, the intrinsic coagulation pathway, complement and fibrinolysis. Activation of the contact pathway produces bradykinin and kallikrein. Activation of the extrinsic and intrinsic coagulation systems produces thrombin and results in the deposition of fibrin. Activation of the complement pathway results in the formation of C5a and the terminal complement complex. These cascades interact with one another and have multiple cellular effects. 8 Leukocytes, platelets, macrophages and endothelial cells are also activated during CPB. Neutrophils are activated by multiple agonists, especially kallikrein and C5a. 8 Activated neutrophils release proteolytic enzymes and reactive oxygen species and adhere to membrane surfaces and endothelial surfaces. 9 Platelets are activated by thrombin and other agonists and undergo shape changes, express surface receptors and secrete granular contents. [10] [11] [12] These platelets adhere to other platelets, neutrophils and exposed basement membranes. 13 Activated macrophages secrete cytokines which in turn activate neutrophils and lymphocytes. Multiple factors, including thrombin, C5a and cytokines, activate endothelial cells that produce vasoactive substances, including nitric oxide (NO) and prostacyclin, and express surface receptors. 14, 15 These acute responses subside as CPB be continues. However, a 2nd or late response also occurs during CPB. The reinfusion of cardiotomy blood from the thoracic wound contributes to the pathogenesis of cardiac vasoplegia. This blood has hemolyzed erythrocytes and macroaggregates consisting of denatured proteins, fat globules and platelet and leukocyte aggregates. These cell fragments and particulates potentially plug small capillaries and stimulate inflammatory responses. In addition, after the cross clamp on the aorta is released, reperfusion of the heart and lung causes an ischemiareperfusion syndrome with neutrophil adherence to activated endothelial cells and the release of reactive oxygen species, which can cause direct protein, lipid and nucleic acid damage. This increases capillary permeability and causes interstitial edema and reduced intravascular volume. Finally, during CPB, endotoxin released from bacteria in the gastrointestinal tract is translocated into the circulation and stimulates inflammation.
The systemic inflammatory response associated with cardiac surgery using CPB causes the formation of fibrin clots and microemboli and produces vascular dysregulation. The inflammatory mediators also cause cardiac, central nervous system, pulmonary, platelet and renal dysfunction. Intraoperative myocardial ischemia, reperfusion and myocardial inflammation-associated elevated troponin I levels after cardiac surgery independently predict in-hospital death and major postoperative complications. 16, 17 These cardiac-related outcomes are likely explained in part by impaired contractility leading to postoperative hemodynamic instability. Interleukin (IL) 6 and IL-8 produced during SIRS have negative inotropic effects, which can lead to poorer cardiac outcomes. 18 However, the primary initial problem in patients with cardiac vasoplegia involves hypotension. Reduced plasma levels of arginine vasopressin (AVP) and excess NO production cause vasodilation after cardiac surgery. 19 The low plasma vasopressin (VP) concentration in these patients has been attributed to reduced VP secretion, possibly secondary to impaired baroreflex-mediated VP secretion. Alternatively, excessive secretion of VP in the early stages of the shock state may have depleted pituitary VP stores. 20, 21 Increased levels of NO and the deficiency of VP lead to the activation of the adenosine triphosphate (ATP)-sensitive K + channel (KATP) in the plasma membrane of vascular smooth muscle. Opening this channel hyperpolarizes vascular smooth muscle and reduces Ca 2+ entry through voltage-gated Ca 2+ channels, which induces vasodilation. 20 NO and other vasodilators, such as atrial natriuretic peptide, cause dephosphorylation of the light chain of myosin by increasing the production cyclic GMP. This prevents actin and myosin interaction and ultimately prevents muscle contraction leading to vasodilation and hypotension. 22 All of these mechanisms contribute to the development of catecholamine-resistant postoperative cardiac vasoplegia. These complex interactions are depicted in part in Figure 1 .
The pathogenesis and clinical features of cardiac vasoplegia resemble severe sepsis and septic shock. Severe sepsis is defined to sepsis-induced tissue hypoperfusion and/or organ dysfunction. Septic shock is defined as a severe sepsis with hypotension, which is refractory to adequate fluid resuscitation. Sepsis creates an intense inflammatory response with the release of the same mediators causing activation of plasma protein systems and cells seen in the cardiac vasoplegia syndrome. Sepsis is, of course, complicated by the active replication of bacteria and the release of exotoxins and endotoxins, but studies in septic patients and models are likely relevant to the investigation and management of cardiac vasoplegia.
Risk Factors
Multiple risk factors for vasoplegia have been identified (Table 1 group likely have acute endothelial dysfunction that impairs the physiological control of the vascular tone. This could reflect activation of the ATP-sensitive potassium channels, the induction of NO and/or a deficiency of VP. Group 3 patients had a rapid decline in BP and a low nadir but responded to clinical interventions. This group may have had mechanical dysfunction secondary to hemodilution and loss of pulsatile perfusion. However, the most significant predictor for cardiac vasoplegia was the mean arterial BP and not the group classification. Additional risk factors for developing vasoplegia syndrome included the additive EuroSCORE, the procedure type, pre-bypass mean arterial pressure, length of bypass, administration of pre-CPB vasopressors, core temperature on CPB, preand post-CPB hematocrit, and the preoperative use of beta blockers or angiotensin-converting enzyme inhibitors. A patient independent risk factor was the type of surgery performed. Compared with coronary artery bypass grafting (CABG), cardiac valvular surgeries and cardiac surgeries specifically intended for the treatment of heart failure, such as heart transplants, ventricular assist device (VAD) implantation and ventriculostomies, were associated with an increased risk for vasoplegia syndrome (OR, 1.52; 95% CI, 1.66-1.99; P 5 0.002 and OR, 2.04; 95% CI, 1.07-3.90; P 5 0.031, respectively). However, aortic graft/repair surgeries protected against the development of vasoplegia (OR, 0.48; 95% CI, 0.29-0.78; P 5 0.003). This protective effect may be explained by hypothermia since hypothermic management during cardiac surgery reduces the risk of vasoplegia (OR 1.11/per 1°C increase in temperature while on CPB). 33 Kortekaas et al 24 studied 40 patients undergoing valvular heart surgery; 15 developed postcardiac surgery vasoplegia. He found pre-existing endothelial cell activation (reflected by higher baseline von Willebrand factor propeptide and sP-selectin levels) is a predisposing factor for postcardiac surgery vasoplegia. The myocardium did not release of endothelial cell activation markers during reperfusion in patients with vasoplegia. In contrast, in patients without vasoplegia, reperfusion increased the release of 3 endothelial cell activation markers, that is, myocardial von Willebrand factor propeptide, osteoprotegerin and IL-8.
Kerbaul et al 25 studied 35 patients who underwent aortic valve replacement using CPB and found adenosine plasma levels were significantly higher in the 7 patients developing vasoplegia syndrome and severe SIRS. This suggests that adenosine release during the systemic inflammatory response associated with cardiac surgery contributes to postoperative vasoplegia. The duration of mechanical ventilation and the length of stay in the intensive care unit were significantly longer in patients with vasoplegia syndrome. Nee et al 26 studied 86 patients undergoing coronary revascularization with CPB. Seventeen patients developed preoperative vasoplegia, and all of them developed postoperative SIRS. Patients with severe postoperative SIRS had increased adenosine and ischemia-modified albumin levels. Severe SIRS after CPB also increases the expression of A2A adenosine receptors, and this amplifies the effect of higher levels of adenosine on the vascular function and contributes to the systemic vasoplegia. 34 Sun et al 27 defined vasoplegia as a mean arterial pressure of #70 mm$Hg, indexed systemic vascular resistance of ,1,400 dynes 3 cm 5 /m 2 , cardiac index of $2.5 L$min 21 $m 22 and central venous pressure of $10 mm$Hg. He reported that the incidence of postoperative vasoplegic syndrome was significantly lower after off-pump CABG surgery (2.8%) than after on-pump CABG surgery (6.9%). In another study, Sun et al 35 found that postoperative vasoplegic syndrome occurred less often after isolated CABG surgery than after open heart surgery (incidence 6.9% versus 17.0%, respectively). They also reported that advanced age and a low preoperative ejection fraction strongly predicted postoperative vasoplegic syndrome.
Patarroyo et al 28 studied 311 patients who underwent orthotopic heart transplantation between January 2003 and June 2008. They defined vasoplegia as persistent low systemic vascular resistance, despite multiple intravenous vasopressors at high doses between 6 and 48 hours after surgery. Thirty-five (11%) patients developed vasoplegia syndrome; these patients were more likely to have United Network for Organ Sharing status 1A, a higher body surface area (P 5 0.0007), a history of thyroid disease (P 5 0.0075) and previous cardiothoracic surgery (P 5 0.0006). Preoperatively, they were more frequently treated with aspirin (P 5 0.005), VADs (P , 0.0001) and total artificial hearts (P , 0.0001) and less frequently treated with milrinone (P 5 0.0005). In the multivariate analysis, a history of thyroid disease (OR, 2.7; 95% CI, 1.0-7.0; P 5 0.04) and VAD before transplant (OR, 2.8; 95% CI, 1.07-7.4; P 5 0.03) were independent risk factors for development of vasoplegia syndrome.
Colson et al 29 studied 64 patients who underwent CPB surgery; 10 patients developed cardiac vasoplegia syndrome. These authors found higher copeptin (a precursor of AVP) plasma concentrations before CPB (P , 0.001) but lower AVP concentrations (P , 0.01) in these patients than in control patients. Cardiac vasoplegic patients also had preoperative hyponatremia and decreased left ventricle ejection fraction and had more complex surgeries. Carell et al 30 studied 800 patients undergoing elective CABG and/or valve replacement; 175 (21.9%) patients developed vasoplegia. In logistic regression analysis, the temperature and duration of CPB, total cardioplegic volume infused, reduced left ventricular function and preoperative treatment with angiotensin-converting enzyme inhibitors predicted the development of early postoperative vasoplegia syndrome. The vasoplegia syndrome did not affect the mortality but did result in higher morbidity and prolonged intensive care unit (ICU) stays.
In summary, we have reviewed 19 studies on cardiac vasoplegia; 11 investigated risk factors and 8 investigated treatment options (Table 2) . These studies included 6,176 patients, and 1,202 patients (19%) developed postoperative cardiac vasoplegia syndrome. Surgical procedures included isolated CABG (2,482 patients), CABG with valve replacement (1,269 patients), isolated valvular surgeries (1,032 patients), orthotopic heart transplant (523 patients), aortic repair (426 patients), heart failure devices (70 patients), reoperations (72 patients) and other surgeries (302 patients). Multiple risk factors for cardiac vasoplegia were identified in these studies (Table 2) . Independent risk factors reported in individual studies included the decline in mean arterial pressure during CPB and the procedure type, which were identified in Levin's large study of 2,823 patients, reduced ejection fraction ,35% reported in 2 studies, preoperative use of intravenous heparin reported in 2 studies, and use of angiotensin-converting enzyme inhibitors reported in 3 studies. Other risk factors associated with vasoplegia are listed in Table 2 . Identifying these risk factors can help physicians predict vasoplegia syndrome in the postoperative setting and consider possible changes in preoperative and postoperative management, such as discontinuing predisposing medications and the use of prophylactic medications, such as VP or methylene blue.
PROGNOSIS
Vasoplegia syndrome carries a poor prognosis, especially norepinephrine-resistant vasoplegia. 32 Catecholamineresistant vasoplegia lasting for more than 36 to 48 hours has a mortality rate as high as 25%. 36 Vasoplegia syndrome is also associated with longer hospital stays, prolonged ICU stays, prolonged mechanical ventilation and more sternal infections. 35 
TREATMENT
The most obvious and immediate problem in patients with cardiac vasoplegia is refractory hypotension. The criteria for treatment and management strategies likely vary significantly in cardiac surgery units and in studies on this syndrome. Levin et al 37 used the following criteria to define vasoplegic syndrome in a study with methylene blue: hypotension, mean arterial pressure less than 50 mm$Hg, low filling pressures, central venous pressure lower than 5 mm$Hg and wedge capillary pressure less than 10 mm$Hg, normal or elevated cardiac index more than 2.5 L$m 21 $m 22 , low peripheral resistance, less than 800 dyn$s 21 $cm 5 and vasopressor requirements. This profile indicates that these patients have distributive shock with vasopressor resistance. Therefore, the initial management of patients with vasoplegia requires vasopressors, which do restore the hemodynamic function in most but not all patients; the most frequently used vasopressors are norepinephrine, VP and phenylephrine (Tables 3 and 4) . 40 However, high doses of these drugs cause serious side effects, such as peripheral or mesenteric ischemia. Egi et al 41 reviewed the literature available through 2006 on the treatment of cardiac vasoplegia and concluded that norepinephrine, high-dose dopamine, phenylephrine, angiotensin II, methylene blue and VP can all increase mean arterial pressure after CPB. They found insufficient evidence to suggest any particular vasopressor was physiologically or clinically superior to the other drugs available. They suggested when the target pressure could not be achieved with the high-dose infusion of 1 drug, a second drug with a different mechanism action should be used. The adverse effects profile of these various drugs seems similar in the available studies. Consequently, initial treatment usually involves volume expansion and the administration of norepinephrine.
Low-dose VP (,0.04 U/min) provides an additional approach because vasoplegia is associated with a reduction in circulating endogenous VP (Table 4) . VP restores vascular tone in vasoplegia syndrome by 4 known mechanisms, including activation of V1 vascular receptors in the vascular smooth muscle cells, modulation of ATP-sensitive K+ channels (KATP), modulation of NO and potentiation of adrenergic and other vasoconstrictor agents leading to vasoconstriction. 42 Because of its rapid onset of action and short half-life, treatment usually requires a continuous infusion. 43 Prophylactic VP infusion (0.03 U/min) starting 20 minutes before the onset of CPB can significantly decrease post-CPB vasopressor support. 38 Papadopoulos et al 44 studied 50 patients undergoing CABG and found that low-dose VP infusion during CPB and for the next 4 hours reduced the requirements for catecholamines and prevented vasoplegia. Noto et al 45 used terlipressin, a long-acting VP analog, to treat 6 patients who developed refractory vasoplegic hypotension after cardiac surgery (Table 5) . Terlipressin normalized the systemic vascular resistance and increased the systemic arterial pressure. Studies in patients with septic shock are potentially relevant to the use of VP in patients with cardiac vasoplegia syndrome. Russell et al 48 reported a very large study comparing VP and norepinephrine in patients with septic shock. This study included 778 patients who had received adequate fluid resuscitation and required at least 5 mg of norepinephrine per minute. These patients were randomized to receiving either low-dose VP or norepinephrine in addition to the open-label vasopressor in place. There was no difference in outcome in either the 28-day mortality or 90-day mortality in these 2 groups. There was no significant difference in the overall rates of adverse effects (approximately 10% in each group). In a subgroup with less severe septic shock, the mortality rate was actually lower in the (8) . Preoperative use of beta blocker 27 Other risk factors (1) . Duration of CPB (2). Higher body mass index (3). Pre-existing endothelial cell activation reflected by higher baseline von Willebrand factor propeptide and sP-selectin level (4). High preoperative capoptin plasma concentration (5). Low AVP concentration (6) . Increased adenosine level (7). Ischemia-modified albumin a Independent risk factors were identified in the multivariate logistic regression model in the reported studies.
OHT, orthotropic heart transplantation; HF, heart failure; VAD, ventricular assist device. 33 
Agent
Mechanism of action Dosage Side effects
Phenylephrine a1-agonist with no b affinity 40-100 mg bolus; 0.5-10 mg/min infusion Peripheral VC; no inotropic action Norepinephrine Potent a1, a2 and modest b1-agonist 4-10 mg bolus; 10-300 ng$kg 21 
$min

21
Gut ischemia, increase PVR, arrhythmias VP group than in the norepinephrine group. The editorial accompanying this article suggested that the timing of treatment was the primary concern for clinicians. 49 Patients with sepsis need immediate treatment when possible. This is likely true in patients with postcardiac surgery vasoplegia.
Methylene blue (Tables 4 and 5 ) provides an alternative drug for the treatment of catecholamine refractory vasoplegia. 39, 50 It interferes with NO metabolism in endothelial and vascular smooth muscle cells. NO is produced in endothelial cells by constitutive and inducible forms of the enzyme NO synthase. NO subsequently activates guanylate cyclase, which leads to vasodilation. 51 Methylene blue binds to NO synthase to decrease NO production and increase systemic vascular tone. 52 Studies have shown that NO is not the only mediator that can activate soluble guanylate cyclase; ILs and oxygen-free radicals also activate this enzyme and cause hyporeactivity in the absence of NO. Methylene blue inhibits soluble guanylate cyclase and can restore vascular tone in vasoplegic scenarios in which NO is not a prominent feature in the pathogenesis. [53] [54] [55] The administration usually involves a single dose of 1.5 to 2 mg/kg; some authors recommend a continuous infusion after the bolus. Levin et al 37 studied 638 cardiac surgery patients at 4 centers. Fifty-six patients developed cardiac vasoplegia defined by hemodynamic criteria with right heart catheterization. Twenty-eight patients received methylene blue (1.5 mg/kg) over 1 hour; 28 patients received placebo. The 2 study groups had identical hemodynamic parameters. Patients treated with methylene blue had no mortality (0% versus 21.4%, P , 0.01) and had reduced renal failure, respiratory failure, encephalopathy, arrhythmias, sepsis and multiorgan failure (all comparisons ,0.05). The mortality in the placebo group occurred after 96 hours in the ICU and was probably explained by sepsis and multiorgan failure. This course could be a consequence of the vasoplegia syndrome or independent nosocomial infections. However, in another study, methylene blue was associated with poor outcomes. 46 This was a retrospective study with 226 patients (57 treated with methylene blue). Patients treated with methylene blue had a higher mortality and morbidity. Analysis of propensity score-matched subgroups (31 treated with methylene blue and 31 untreated patients) demonstrated that patients receiving methylene blue had higher total morbidity, lung morbidity (tracheostomy, pneumonia and reintubation), hyperbilirubinemia (.12 mg/dL) and days of inotropic support (P values ,0.05 for respective ORs). The authors speculate that inhibition of NO could also have deleterious effects on microvascular function. However, this was a retrospective study without hemodynamic data or a standardized care protocol for these patients. The indications for the use of methylene blue likely depended on physician preference and other unknown factors. In addition, in these complicated patients, management details and the timing of interventions are crucial to determine the best treatment strategy. In general, these patients need urgent treatment regardless of the drug used. Methylene blue interferes with pulse oximetry reading, leading to falsely low reading, and other methods for monitoring tissue oxygenation are needed if this drug is used. 56 Corticosteroids significantly reduce the inflammatory response associated with CPB. 57 These drugs reduce IL-1, IL-6, tumor necrosis factor, leukotriene and endotoxin levels and increase anti-inflammatory mediators, such as IL-10. Teoh et al 58 studied the effect of steroids on cytokine release in patients undergoing coronary artery bypass surgery with CPB. Sixteen patients received 250 mg of methylprednisolone IV at the induction of anesthesia; 9 patients received no steroid treatment. IL-6 and tumor necrosis factor (TNF)-a increased after surgery, peaked at 6 hours and remained elevated for approximately 24 hours. IL-6 levels and TNF-a were lower throughout this time frame in patients receiving methylprednisolone. Postoperative mean BPs were higher in patients receiving methylprednisolone, cardiac indices were lower and systemic vascular resistances were higher. There were reasonable correlations between the elevation in IL-6 and cardiac index, systemic vascular resistance and temperature. Therefore, this study demonstrates that methylprednisolone reduces the production of cytokines and associated changes in hemodynamic parameters in patients undergoing normothermic cardiac surgery with CPB. Ho and Tan reviewed 50 randomized control trials of corticosteroid prophylaxis in patients undergoing cardiac surgery requiring CPB, which included 3,323 patients. Corticosteroids were associated with a reduction in C reactive protein levels (244.2 mg/L) and in IL-6 concentrations (2148 pg/mL). Corticosteroid prophylaxis reduced the risk of atrial fibrillation (25.1% versus 35.1%), the length of stay in the intensive care unit (20.37 days) and the length of stay in the hospital (20.66 days). Corticosteroid prophylaxis reduced the duration of mechanical ventilation (20.68 hours). However, a dose-response analysis indicated that higher doses of steroids prolonged mechanical ventilation by 2.1 hours. Corticosteroids were not associated with the increase in infections but were associated with an increase in hyperglycemia (relative risk 5 1.49).
59 These 2 studies demonstrate that corticosteroid prophylaxis in patients undergoing cardiac surgery requiring CPB reduces the acute inflammatory response, improves postoperative hemodynamic parameters and slightly reduces the time required for mechanical ventilation and hospital stay. These reductions in the length of stay were modest and of uncertain significance. These drugs seem to have a greater effect on the prevention of atrial fibrillation than on other clinical parameters. The increase in hyperglycemia would potentially require management protocols. The Dexamethasone for Cardiac Surgery trial recruited 4,494 patients and 8 surgical hospitals in the Netherlands. 60 These patients received a single intraoperative dose of dexamethasone or placebo. There is a trend toward improvement in the primary outcome, which was a composite of death, myocardial infarction, stroke, renal failure and respiratory failure (relative risk, 0.83; 95% CI, 0.67-1.01; P 5 0.07). Steroid treatment did reduce the frequency of infection, delirium and respiratory failure. This study indicated that steroid prophylaxis was safe. A 2nd large study entitled Steroids in Cardiac Surgery is near completion. 57 This study will enroll 7,500 patients into treatments with either methylprednisolone (250 mg given in 2 doses) or placebo. The primary outcome is 30-day mortality in high-risk patients and defined by a EuroSCORE greater than 6. These 2 very large trials should eventually clarify the role of corticosteroids in the prevention of postcardiac surgery complications, including the cardiac vasoplegia syndrome. Prophylaxis may be most useful in patients with risk factors for cardiac vasoplegia. 
CONCLUSIONS
Postcardiac surgery vasoplegia is a relatively common and well-recognized syndrome. Several patient-dependent and procedure-related risk factors can predict the development of this syndrome. Norepinephrine and phenylephrine are the most commonly used drugs to treat postcardiac surgery hypotension. However, catecholamine refractory vasoplegia can occur and has high morbidity and mortality rates. VP, methylene blue and terlipressin have been used to treat catecholamine-resistant vasoplegia, but more studies are needed to evaluate these drugs in the treatment of this complication. On going trials with corticosteroid prophylaxis may provide definitive evidence about the use of these drugs in either the prevention or management of this syndrome.
KEY POINTS
1. Cardiac vasoplegia syndrome can occur after any cardiac surgery, particularly in surgery requiring CPB. 2. Understanding the pathophysiology and risk factors for vasoplegia can help us identify patients at high risk for developing vasoplegia after CPB. 3. The severity and duration of the decrease in mean arterial BP immediately after the beginning CPB can be used to identify patients likely to develop post-CPB vasoplegia. 4. The development of catecholamine refractory vasoplegia is associated with high morbidity and mortality. 5. Vasopressors have been the main therapy for vasoplegia syndrome; more studies are needed to evaluate the safety and effectiveness of methylene blue and VP for the treatment of this syndrome. 6. On going trials may demonstrate that prophylactic corticosteroids reduce the morbidity and mortality associated with this syndrome.
